At ESMO 2024, Amanda Nizam, MD, from the Cleveland Clinic and Jørgen Bjerggaard Jensen, MD, from Aarhus University discuss the TOMBOLA trial, assessing early post-cystectomy immunotherapy according to ctDNA status in muscle-invasive bladder cancer. Dr. Jensen highlights the single-arm trial design, details the trial’s use of ctDNA, and elaborates on how TOMBOLA fits into the larger context of other trials in bladder cancer. ...
Urothelial Carcinoma
Advertisement
Latest News
Dr. Hussain provides his thoughts on how and why to increase worldwide attention on rare forms of bladder cancer.
Dr. Hussain summarizes his presentation on rare and predominant variant histologies in bladder cancer.
Dr. Galsky discusses the value of HER2 status and the promising 75% ORR from the phase 2 trial.
Additional evidence for neoadjuvant therapy for patients undergoing RC, ineligible for neoadjuvant platinum-based chemo.
Dr. Coen explains the low cystectomy rates and high bladder-intact survival in both treatment arms.
Perioperative durvalumab with NAC offers “meaningful improvement” in EFS and OS for patients with cisplatin-ineligible ...
Advertisement
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Dr. Hussain provides his thoughts on how and why to increase worldwide attention on rare forms of bladder cancer.
Dr. Hussain summarizes his presentation on rare and predominant variant histologies in bladder cancer.
Dr. Galsky discusses the value of HER2 status and the promising 75% ORR from the phase 2 trial.
Additional evidence for neoadjuvant therapy for patients undergoing RC, ineligible for neoadjuvant platinum-based chemo.
SPLASH continues to show benefit for PSMA RLT in mCRPC and adds to this consideration in the pre-chemotherapy setting.
The TiNivo-2 trial found that a tivozanib-nivolumab combination therapy did not improve outcomes over tivozanib alone.
Advertisement
Advertisement
Latest News
Dr. Hussain provides his thoughts on how and why to increase worldwide attention on rare forms of bladder cancer.
Dr. Hussain summarizes his presentation on rare and predominant variant histologies in bladder cancer.
Dr. Galsky discusses the value of HER2 status and the promising 75% ORR from the phase 2 trial.
